cd5 car t
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren HospitalCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the T-Cell Acute Lymphoblastic Leukemia/Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Sanofi | Phase 2 | B |
Venetoclax First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
Cytosin-Arabinosid First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
RANITIDINE Sanofi | Phase 2 | CCC |
Omacetaxine First Affiliated Hospital of Zhejiang University | Phase 2 | CCC |
View all 19 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →